Bio-Techne Corp. (TECH) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein s...
Bio-Techne Corp. (TECH) currently trades at a P/E ratio of 103.87 (historical range: 34.68–137.95, median: 64.18), placing it at the 85th percentile — expensive relative to its history, P/S ratio of 9.40 (range: 5.61–25.73, 37th percentile — below its historical average), EV/EBITDA of 41.48 (range: 28.38–105.49, 17th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Bio-Techne Corp.'s P/E ratio has expanded by 32% over the observed period (from an average of 61.9 to 81.5).
Bio-Techne Corp. trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 103.87 | 64.18 | 85th | expensive relative to its history |
| P/S Ratio | 9.40 | 10.23 | 37th | below its historical average |
| EV/EBITDA | 41.48 | 48.92 | 17th | cheap relative to its history |
| FCF Yield | 2.37% | 2.11% | 69th | below its historical average |
Bio-Techne Corp. (TECH) Valuation & P/E History
Bio-Techne Corp. (TECH) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry currently trading at $72.57 with a market capitalization of $11.4 billion. This page provides historical valuation analysis for TECH based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 103.87 is above the historical median of 64.18, placing TECH at the 85th percentile of its valuation range. The P/S ratio of 9.40 compares to a median of 10.23.
TECH Valuation Metrics & Historical Range
The valuation table above shows Bio-Techne Corp.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether TECH is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests TECH is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Bio-Techne Corp..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is TECH Overvalued or Undervalued?
Bio-Techne Corp. trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 46 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive TECH is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full TECH analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.TECH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.